These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30238372)

  • 21. Regulatory biocompatibility requirements for biomaterials used in regenerative medicine.
    Williams DF
    J Mater Sci Mater Med; 2015 Feb; 26(2):89. PubMed ID: 25649511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Balancing Safety and Innovation for Cell-Based Regenerative Medicine.
    Marks P; Gottlieb S
    N Engl J Med; 2018 Mar; 378(10):954-959. PubMed ID: 29514023
    [No Abstract]   [Full Text] [Related]  

  • 23. Workshop to address gaps in regulation of minimally manipulated autologous cell therapies for homologous use in Canada.
    Chisholm J; von Tigerstrom B; Bedford P; Fradette J; Viswanathan S
    Cytotherapy; 2017 Dec; 19(12):1400-1411. PubMed ID: 28964743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The government's role in advancing regenerative medicine and tissue engineering - science, safety, and ethics.
    Smith DS
    Periodontol 2000; 2006; 41():16-29. PubMed ID: 16686924
    [No Abstract]   [Full Text] [Related]  

  • 25. Regulation Policy on Cell- and Tissue-Based Therapy Products in Korea.
    Lim JO
    Tissue Eng Part A; 2015 Dec; 21(23-24):2791-6. PubMed ID: 25759938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory and microbiological safety issues surrounding cell and tissue-engineering products.
    Galbraith DN
    Biotechnol Appl Biochem; 2004 Aug; 40(Pt 1):35-9. PubMed ID: 15270705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical biosafety evaluation of cell-based therapies: emerging global paradigms.
    Basu J; Assaf BT; Bertram TA; Rao M
    Toxicol Pathol; 2015 Jan; 43(1):115-25. PubMed ID: 25476796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation Policy on Tissue Engineering and Regenerative Medicine in Asian-Pacific Region.
    Liu W; Burdick JA; van Osch GJ
    Tissue Eng Part A; 2015 Dec; 21(23-24):2779-80. PubMed ID: 26486210
    [No Abstract]   [Full Text] [Related]  

  • 29. Preparing regenerative therapies for clinical application: proposals for responsible translation.
    Shapiro SA; Smith CG; Arthurs JR; Master Z
    Regen Med; 2019 Feb; 14(2):77-84. PubMed ID: 30651044
    [No Abstract]   [Full Text] [Related]  

  • 30. [Supervision, administration and standard research related to tissue engineered medical products].
    Xi TF; Chen L; Zhao P
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2003 Nov; 17(6):480-7. PubMed ID: 14663949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving the biocompatibility of biomaterial constructs and constructs delivering cells for the pelvic floor.
    Mangir N; Roman S; MacNeil S
    Curr Opin Urol; 2019 Jul; 29(4):419-425. PubMed ID: 30950867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [International approaches to the regulation of cell therapy products].
    Piatigorskaia NV; Tulina MA; Aladysheva ZhI; Beregovykh VV
    Vestn Ross Akad Med Nauk; 2013; (8):4-8. PubMed ID: 24340637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Premarket Regulation of Tissue Engineered Medical Products in China.
    Wang C; Wang A; Feng X; Ke L; Huang Y; Han Q; Sun X; Yang Z
    Tissue Eng Part A; 2015 Dec; 21(23-24):2806-11. PubMed ID: 26529310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation Policy for Cell and Tissue Therapies in Australia.
    Sturm M
    Tissue Eng Part A; 2015 Dec; 21(23-24):2797-801. PubMed ID: 26096750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell and gene therapy manufacturing capabilities in Australia and New Zealand.
    O'Sullivan GM; Velickovic ZM; Keir MW; Macpherson JL; Rasko JEJ
    Cytotherapy; 2019 Dec; 21(12):1258-1273. PubMed ID: 31806531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Institutional profile. The International Society for Cellular Therapy: evolving to meet the demands of the regenerative medicine industry.
    Maziarz RT; Arthurs J; Horwitz E
    Regen Med; 2011 Mar; 6(2):163-6. PubMed ID: 21391849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Organ Chips: Quality Assurance Systems in Regenerative Medicine.
    Pasqualini FS; Emmert MY; Parker KK; Hoerstrup SP
    Clin Pharmacol Ther; 2017 Jan; 101(1):31-34. PubMed ID: 27709615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Component therapy to cellular therapy and beyond- a Darwinian approach to transfusion medicine.
    Snyder EL
    Transfusion; 2008 Sep; 48(9):2000-7. PubMed ID: 18694467
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA faces regulatory challenges with new approaches to medicine.
    Roehr B
    BMJ; 2014 Feb; 348():g1530. PubMed ID: 24531207
    [No Abstract]   [Full Text] [Related]  

  • 40. Innovative regenerative medicines in the EU: a better future in evidence?
    Corbett MS; Webster A; Hawkins R; Woolacott N
    BMC Med; 2017 Mar; 15(1):49. PubMed ID: 28270209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.